3 stories mentioning MBXUpdated 48d ago
Every FINWIRES story that references MBX, newest first.
MBX Biosciences (MBX) shares were about 1.0% lower in Thursday trading following its Q2 results.Earlier, the clinical-stage biopharmaceutical company reported a Q2 net loss of $0.78 per share, compared with a loss of $0.58 a year ago.Looking ahead, the firm said its cash and investments are expected to support operations into 2029.Price: $66.78, Change: $-0.70, Percent Change: -1.04%
MBX Biosciences (MBX) on Monday named executive chairman Steve Hoerter as chairman and chief executive officer, succeeding co-founder Kent Hawryluk, who will step down as president, chief executive officer and a member of board.The company said it also appointed John Smither, currently interim CFO, as chief financial officer. The executive changes are effective immediately.
Salomon Azoulay, Chief Medical Officer, on May 08, 2026, sold 70,003 shares in Mbx Biosciences (MBX) for $2,685,515. Following the Form 4 filing with the SEC, Azoulay has control over a total of 14,769 common shares of the company, with 14,769 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1776111/000119312526216704/xslF345X05/ownership.xml
